SCHEMBL1322157

SCHEMBL1322157

CC(=O)c1cccnc1N

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 2/20 0.68
PRKCI P41743 2/20 0.59
NOS3 P29474 1/20 0.48
NOS1 P29475 1/20 0.48
NOS2 P35228 1/20 0.48
VCP P55072 4/20 0.46
P2RX7 Q99572 1/20 0.46
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
BLM P54132 1/20 0.44
AGER Q15109 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29489950 1.00 NAPRT (0.68) NAPRTPRKCINOS3NOS1NOS2
Boric Acid SCHEMBL28116595 0.87 NAPRT (0.53) NAPRTPRKCINOS3NOS1NOS2
SCHEMBL12750468 0.83 NAPRT (0.53) NAPRTPRKCINOS3NOS1NOS2
SCHEMBL8198020 0.83 NAPRT (0.73) NAPRTPRKCINOS3NOS1NOS2
SCHEMBL19226018 0.81 NAPRT (0.59) NAPRTPRKCINOS3NOS1NOS2
SCHEMBL11098869 0.81 NAPRT (0.70) NAPRTPRKCINOS3NOS1NOS2
SCHEMBL219457 0.81 NAPRT (1.00) NAPRTPRKCINOS3NOS1NOS2
SCHEMBL29530139 0.81 NAPRT (1.00) NAPRTPRKCINOS3NOS1NOS2
SCHEMBL310265 0.81 NAPRT (0.70) NAPRTPRKCINOS3NOS1NOS2
SCHEMBL30901792 0.81 NAPRT (0.70) NAPRTPRKCINOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521307-B Preparation method of 5-halogeno-7-azaindole 甘肃皓天医药科技有限责任公司 2023-09-22 CN claimed
CN-115418642-B Copper-molybdenum etching solution and preparation method thereof 湖北兴福电子材料股份有限公司 2023-06-02 CN claimed
CN-115521307-A Preparation method of 5-halogenated-7-azaindole 甘肃皓天医药科技有限责任公司 2022-12-27 CN claimed
CN-115418642-A Copper-molybdenum etching solution and preparation method thereof 湖北兴福电子材料股份有限公司 2022-12-02 CN claimed
CN-109456320-A A kind of synthetic method of medicine intermediate 7- azaindole 嘉兴市秀洲区洪合镇中学 2019-03-12 CN claimed
WO-2007146230-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-12-21 WO claimed
EP-4735451-A1 SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS Kumquat Biosciences Inc. (US) 2026-05-06 EP disclosed
US-12440491-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2025-10-14 US disclosed
EP-4605400-A1 NOVEL TRIHETEROCYCLIC COMPOUNDS Idience Co., Ltd. (KR) 2025-08-27 EP disclosed
US-20250186408-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-06-12 US disclosed
US-20250101012-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2025-03-27 US disclosed
CN-119462645-A Tetrahydro-beta-carboline bacteriostatic agent, and synthesis method and application thereof 江苏科技大学 2025-02-18 CN disclosed
WO-2025007000-A1 SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS KUMQUAT BIOSCIENCES INC. (US) 2025-01-02 WO disclosed
US-20080020985-A1 PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF MYRIAD GENETICS, INC. (US) 2008-01-24 US disclosed
EP-1833803-A2 PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF MYRIAD GENETICS, INC. (US) 2007-09-19 EP disclosed
EP-1790650-A1 NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed
EP-1724268-A1 COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-22 EP disclosed
WO-2006074223-A2 PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF MYRIAD GENETICS, INC. (US) 2006-07-13 WO disclosed
CN-1255042-A Diaryl ethers and processes for their preparation and herbicidal and desiccant compositions containing them ISK AMERICAS INC (US) 2000-05-31 CN disclosed
CN-1043344-C New heterocyclic compounds KRONSEDER MASCHF KRONES (JP) 1999-05-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101012-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS ERG28, DPM1, CYP51A1 NAPRT 25/4885PRKCI 4157/4885NOS3 1182/4885
US-20250186408-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY CNR1, CNR2, CYP2J2 NAPRT 1446/4885PRKCI 1778/4885NOS3 1493/4885
US-12440491-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS NAPRT 2709/4885PRKCI 216/4885NOS3 4868/4885
US-20080020985-A1 PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CASP3, CASP2, CASP5 NAPRT 2774/4885PRKCI 900/4885NOS3 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.